SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

Abroad (travel likely)RecruitingPHASE2

Conditions

Rectal Cancer · Rectal Adenocarcinoma · Rectal Cancer, Radiotherapy · Rectal Cancer Patients · Immunotherapy · Total Neoadjuvant Therapy · Total Neoadjuvant Treatment · Targeted Therapy · Chemoradiotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Contact: Study coordinator (Bo Feng) · Fengbo2022@163.com · +86 21 64370045

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

Rectal Cancer · Total Neoadjuvant Therapy · Radiotherapy

Abroad (travel likely)RecruitingPHASE3

Wuhan, China

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Rectal Cancer · Radiotherapy

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Rectal Cancer

Abroad (travel likely)Recruiting

Strasbourg, France